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Abstract
Background: Understanding fate choice and fate switching between the osteoblast lineage (ObL) and adipocyte lineage
(AdL) is important to understand both the developmental inter-relationships between osteoblasts and adipocytes and the
impact of changes in fate allocation between the two lineages in normal aging and certain diseases. The goal of this study
was to determine when during lineage progression ObL cells are susceptible to an AdL fate switch by activation of
endogenous peroxisome proliferator-activated receptor (PPAR)c.
Methodology/Principal Findings: Multiple rat calvaria cells within the ObL developmental hierarchy were isolated by either
fractionation on the basis of expression of alkaline phosphatase or retrospective identification of single cell-derived
colonies, and treated with BRL-49653 (BRL), a synthetic ligand for PPARc. About 30% of the total single cell-derived colonies
expressed adipogenic potential (defined cytochemically) when BRL was present. Profiling of ObL and AdL markers by qRT-
PCR on amplified cRNA from over 160 colonies revealed that BRL-dependent adipogenic potential correlated with
endogenous PPARc mRNA levels. Unexpectedly, a significant subset of relatively mature ObL cells exhibited osteo-
adipogenic bipotentiality. Western blotting and immunocytochemistry confirmed that ObL cells co-expressed multiple
mesenchymal lineage determinants (runt-related transcription factor 2 (Runx2), PPARc, Sox9 and MyoD which localized in
the cytoplasm initially, and only Runx2 translocated to the nucleus during ObL progression. Notably, however, some cells
exhibited both PPARc and Runx2 nuclear labeling with concomitant upregulation of expression of their target genes with
BRL treatment.
Conclusions/Significance: We conclude that not only immature but a subset of relatively mature ObL cells characterized by
relatively high levels of endogenous PPARc expression can be switched to the AdL. The fact that some ObL cells maintain
capacity for adipogenic fate selection even at relatively mature developmental stages implies an unexpected plasticity with
important implications in normal and pathological bone development.
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Introduction
Multipotent mesenchymal stem cells differentiate into osteo-
blasts, adipocytes and other mesenchymal lineages, and key
transcription factors underlie commitment and fate choices of cells
to particular lineages with suppression of alternative lineages
[1,2,3]. Considerable evidence supports the notion that osteoblasts
and adipocytes are closely related through a common progenitor.
For example, a decrease in bone volume in age-related and
steroid-induced osteoporosis is accompanied by an increase in
marrow adipose tissue (see for example, [4,5]). A variety of
experimental manipulations in primary bone marrow stromal cells
and cell lines have contributed molecular and cellular insight into
the mechanisms underlying the apparent reciprocal relationship
between the two lineages (see for example, [1,6,7,8,9,10,11]).
These studies have led to the suggestion that regulated lineage
allocation of stem or multipotential progenitor cells or a fate switch
from osteoblast lineage (ObL) to adipocyte lineage (AdL) occurs
under certain conditions, including aging. However, it is unclear at
what commitment or differentiation stage(s) fate changes occur.
Peroxisome-proliferator activated receptor (PPAR)c, a ligand-
activated transcription factor belonging to the nuclear hormone
receptor superfamily, is expressed principally in adipose tissue and
heterodimerizes with a retinoid X receptor to bind the PPAR
response elements within the promoters of target genes, including
adipocyte-associated genes. Thus, PPARc (PPARc2, in particular)
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together with other transcription factors, such as PPARa and
CCAAT enhancer-binding proteins (C/EBPs) [12,13,14]. Thia-
zolidinediones, anti-diabetic agents including rosiglitazone (BRL-
49653 (BRL)), are frequently used synthetic ligands for PPARc
[15] and stimulate adipogenesis and inhibits osteoblastogenesis in
vivo and in vitro [8,9,10,11]. This may be implicated in
downregulation of runt-related transcription factor 2 (Runx2) in
a bone marrow-derived cell line overexpressing PPARc2 [16].
Evidence from PPARc haploinsufficient mice also supports the
concept that PPARc is antagonistic to osteogenesis, acting early in
mesenchymal cell differentiation [1]. In contrast, microarray
analysis of mesenchymal lineage markers in mouse calvaria cell
cultures indicates that adipocyte- (except PPARc) but not
myocyte-asssociated genes are transcriptionally induced together
with osteoblast-associate genes during osteoblast development
[17]. Similarly, our recent data show that adipocytes emerge along
with osteogenic potential in a fraction of fetal rat calvaria cells
treated with BRL [18]. Developmental regulation of calvaria cells,
a frequently used model of ObL cells, is different in at least certain
respects, from that of marrow stromal cells, suggesting that these
diverse results may reflect differences in PPARc regulation of
osteo-adipogenic fate choice in the two organs. However,
dissecting when during ObL lineage progression cells may be
susceptible to fate switches is complicated by the fact that although
osteoblast differentiation is well characterized [19], phenotypic
heterogeneity of ObL cells is seen in multiple cell culture models,
including stromal and calvarial cells, as well as in developing rat
calvariae [20]. This heterogeneity includes cellular responses to
cytokines and hormones (e.g., parathyroid hormone (PTH)/PTH
related protein receptor in cortical versus trabecular bone
compartments [21]).
Based on all of these data, we hypothesized that subsets of ObL
cells may differentially respond to PPARc. By preparing ObL cells
at multiple differentiation stages from rat calvariae either by
magnetic cell sorting using anti-alkaline phosphatase (ALP, a
marker of relatively early ObL progression) antibody or by replica
plating of single cell-derived colonies, we identified and charac-
terized a distinct subset of ObL cells that can convert into
adipocytes in the presence of BRL.
Results
Multiple cellular pathways lead to adipogenesis in ObL
cells
As described previously [18], ObL cells from fetal rat calvariae
proliferated (day 0–5), reached confluence and subsequently
formed cell condensations (day 5–6), followed by nodule formation
(differentiation, day 6–10) (Fig. S1) and mineralization (matura-
tion, not shown). This developmental process was also confirmed
by gene expression profiling of osteoblast markers (Fig. S2A). ObL
cells chronically treated with BRL were morphologically similar to
those without BRL up to day 5–6, and thereafter adipocytes were
seen within cell condensations (Fig. S1). In contrast to what was
seen in BRL-treated cultures, a very few adipocytes were dispersed
in control cultures without BRL, but they disappeared as ObL
progression occurred (data not shown). Likewise, colony formation
assays revealed that there were only a few colony-forming unit
(CFU)-adipocyte colonies without BRL (Fig. 1A). BRL, however,
increased not only CFU-adipocyte (Fig. 1A) but also CFU-ALP
colonies (Fig. 1B,C). When we treated cells in which mineralized
nodules had already formed with BRL for 5 days, a few adipocytes
were present within some of the mineralized nodules (Fig. 1D),
raising the possibility that adipocytes may arise even from
relatively mature ObL cells. To separate mature ObL cells from
multipotential progenitors (e.g., side population cells [22]), and
other potentially contaminating lineages present in the primary
cell digestion, we next released cells by enzymatic digestion from
nodule-forming cells (day 10), and separated them into ALP-
positive (ALP
+) and ALP-negative (ALP
2) fractions [23] by
magnetic cell sorting (Fig. 1E). Adipocytes formed diffusely
(Fig. 1F) in all fractions treated with BRL, although the number
of adipocytes present varied with ALP
2.control/unfractionate-
d.ALP
+ (Fig. 1G).
To define whether adipogenic potential is restricted to a specific
subset of ObL cells, we used a combination of single cell colony
assays and replica plating [24,25]. ObL colonies were retrospec-
tively identified by ALP/von Kossa staining of their corresponding
replicas (Fig. 1H). Cells in individual colonies displayed homog-
enous morphology (Fig. 1I) and ALP activity, i.e., colonies
comprised ,100% ALP
2 or ALP
+ cells (Fig. 1J). Over 160
colonies from 12, 15, 17, and 21 days of culture were collected in
each of two independent experiments; a portion of cells of each
colony was re-plated at high cell density with BRL, while the
remainder was collected for total RNA preparation. One hundred-
fifteen and 132 colonies in each experiment were successfully
adapted to subculture, and of these, 94 and 95 respectively were
designated osteoblast lineages, as verified by replica dishes
(Table 1).
Definitive ObL colonies subcultured and treated with BRL were
classified into four categories based on ALP and oil red O staining:
single ALP
+ is defined as osteogenic (32/97 and 42/95 in
experiment 1 and 2 respectively); oil red O
+ is adipogenic (19/
97 and 11/95); double positive ALP
+/oil red O
+ are osteo-
adipogenic colonies (30/97 and 26/95), and double negative
ALP
2/oil red O
2 are neither osteo- nor adipogenic (16/97 and
16/95) (Table 1 and Fig. 1K). Notably, colonies picked and
subcultured at day 12 exhibited mainly monopotential adipogenic
fate at subculture, while colonies picked on day 21 were mainly
monopotential but for osteogenic fate. Double-positive colonies/
bipotential fate occurred mainly in colonies isolated at days 15, 17
and 21. Taken together, the results suggest that some ObL cells,
including cells already partially differentiated/maturing, can adopt
an adipo/osteogenic fate, but that mature osteoblasts have a much
lower probability to do so, at least under the conditions tested.
Gene expression profiling of single cell-derived colonies
and its relationship to osteo/adipogenic potential
We next used real-time quantitative RT-PCR (qRT-PCR) to
analyze expression of osteo-adipogenic markers and transcription
factors necessary for mesenchymal lineage progression in repre-
sentative colonies (97 ObL colonies subcultured in experiment 1,
Table S1). Based on their osteoblast marker expression and the
established osteoblast hierarchy [19], colonies were rearranged
into an order from early (immature) to late stages of ObL
progression, i.e., immature (negative for all of ALP, bone
sialoprotein (BSP) and osteocalcin (OCN)), intermediate (negative
for either ALP, BSP, or OCN) or mature (positive for all osteoblast
markers) colonies (Fig. 2). It is important to note that all colonies
listed were committed to the ObL, as evidenced by Runx2 gene
expression and ALP/von Kossa staining outcomes in replica
dishes as described above. About 20% of colonies in subcultures
supplemented with BRL were double negative (Table 1) and had
fibroblastic morphology (not shown). There was a clear develop-
mental stage dependency in the frequency with which osteo-
adipogenic mono- or bipotential colonies occurred; analysis by
expression profiling was similar to, but more robust than, what was
detected by cytochemistry (Table S1 and Fig. 2). There were
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colonies that gave rise to either ALP
+ or oil red O
+ and between
ALP
+/oil red O
+ and oil red O
+ colonies in BRL-treated matched
subcultures (Table 2). Further, PPARa mRNA levels in colonies
monopotential for adipogenic fate (oil red O
+) were significantly
higher than those in colonies defined as osteo-adipogenic
bipotential (Table 2). In contrast, C/EBPs expression levels and
osteo-adipogenic activities were poorly or not correlated (Table 2).
Taken together, the data suggest that the adipogenic potential of
ObL cells may be defined by the relative levels of PPARc and
PPARa versus other marker mRNAs.
To confirm that adipogenic fate of ObL cells is defined by
relative levels of PPARc and PPARa, we co-treated rat calvaria
cells with BRL plus rabbit serum (RS), the latter known to
stimulate PPARa gene expression [26]; co-treatment resulted in an
inverse relationship between the number of bone nodules
(decrease) and adipocyte colonies (increase) that formed
(Fig. 3A,B) with no effect on total colony number (Fig. 3C).
Amongst PPAR and C/EBP family members, PPARa and C/
EBPd mRNA levels were increased by RS (Fig. 3D). However,
fenofibrate, a synthetic PPARa ligand [27], combined with BRL,
did not fully mimic the RS plus BRL effect (Fig. 3E,F), suggesting
that RS may elicit other activities, including induction of C/EBPd,
to induce adipogenesis. In any case, our results indicate that
committed ObL cells unambiguously defined by marker expres-
sion profile and functional endpoints exhibit diverse molecular
phenotypes as characterized by expression of non-osteoblastic
mesenchymal lineage markers. That the diversity extends beyond
adipogenic regulatory genes was confirmed by profiling two
transcription factors involved in myogenesis (MyoD) and chon-
drogenesis (Sox9); these were also expressed in 22 and 20% of
osteogenic colonies in developmentally immature (stage 1) and
intermediate (stage 2) stages respectively (one colony expressed
both), but not in any colonies at mature stages (Fig. S3).
Figure 1. BRL induces adipocytes in ObL cells. (A–C) RC cells in 96-well plates (150 cells/well) were cultured in osteogenic medium with or
without 1–100 nM BRL for 10 days. (A) Percentage of wells containing CFU-adipocyte. (B) Representative stereoscopic images of CFU-ALP colonies. (C)
Number of CFU-ALP per well. n=32 wells/treatment. *p,0.05, compared to control (vehicle alone). (D) Adipocytes within mineralized bone nodules.
Cells were treated with 100 nM BRL for 5 days after mineralized bone nodules had formed (day 14). Phase-contrast microscopic images; lower panel,
the enlargement of adipocytes (arrow) in upper panel. (E–G) RC cells at day 10 were fractionated by magnetic cell sorting with anti-ALP antibody
(aALP) or normal IgG (control). (E) Quantification of ALP activity in ALP
+, ALP
2 and control fractions. (F) ALP (blue)/oil red O (red)-double staining in
ALP
+ (aALP+) and ALP
2 (aALP-) fractions shown by stereoscopy. The remainder of each fraction in (E) was cultured in osteogenic medium with
100 nM BRL for a week. (G) Percentage of wells containing adipocyte colonies in the ALP
+, ALP
2 and control fractions. n=16 wells/fraction.
***p,0.001, **p,0.01 and *p,0.05, compared to control (IgG). (H–K) RC cells at very low density (#15 cells/cm
2 in 100-mm dishes) in osteogenic
medium plus 10 nM Dex (master dishes). A few days later, polyester cloths were overlaid on master dishes for a day to make replicas. 10 mM bGP was
added into replica dishes. (H) Master and replica dishes. Master and replica dishes (day 25) were fixed and stained with hematoxylin and ALP/von
Kossa, respectively. Arrowheads and numbers in each dish indicate examples of matched pairs of colonies. (I) Phase-contrast microscopy of single
cell-derived colonies in the master dish on day 17. Left and right panels show typical monolayer and multilayer colonies, respectively. (J) ALP
+ (left)
and ALP
2 (right) colonies in the master dish on day 15. (K) Osteo-adipogenic potential in osteoblast-lineage colonies. Subcultures from individual
colonies were maintained for a week in osteogenic medium with 100 nM BRL. Left panel, ALP staining of cells from a colony on day 21. Right panel,
oil red O staining of cells from a colony on day 12.
doi:10.1371/journal.pone.0011782.g001
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stage are molecularly and functionally distinct
By assessing single cell-derived colonies, we showed that rat
calvaria cells comprise a heterogeneous mixture of ObL cells with
different gene expression profiles and different potential for fate
switching. However, as is well-established [19], the rat calvaria cell
population expresses a temporally reproducible sequence of
osteoblast development (see description above and the sequential
upregulation of oteopontin (OPN), ALP and OCN in Fig. S2A).
We therefore also assessed mRNA expression of mesenchymal
lineage-commitment transcription factors, such as Runx2, PPARc,
Sox9 and MyoD in this model (Fig. S2A). In contrast to Runx2,
which increased slightly during the differentiation time course,
Sox9 and MyoD were highest early (day 3) and progressively
decreased thereafter. Levels of PPARc1 and c2 peaked at day 6
and subsequently decreased. Western blot analysis confirmed that
Runx2 and PPARc protein expression paralleled that of their
mRNAs (Fig. S2B).
Immunofluorescence staining of proliferating rat calvaria cells
(day 3) with antibodies against the same transcription factors
revealed that all were localized in the cytoplasm (Fig. 4A). All four
factors were also present in cells in nodules, however the number
of cells with detectable expression of PPARc, Sox9 and MyoD in
nodules was fewer than those expressing Runx2 (Fig. 4B). In
subcultures of more mature cells from nodules (see above, ALP
+
fractions), Runx2 was clearly located in the nucleus, but other
Table 1. Summary of colony types and developmental fate of single cell-derived rat calvaria cell colonies.
Colony types Number of colonies
Experiment 1 Experiment 2
(Days) 12 15 17 21 12 15 17 21
Total, recovered from master dishes 51 (18) 34 (30) 42 (34) 41 (39) 55 (11) 39 (32) 38 (35) 40 (38)
Total, subcultured successfully 26 (17) 29 (26) 34 (26) 28 (28) 33 (8) 31 (23) 30 (28) 38 (36)
ALP positive 1 (1) 3 (3) 7 (7) 21 (21) 3 (2) 5 (5) 7 (7) 28 (28)
Oil red O positive 16 (14) 3 (3) 2 (2) 0 (0) 11 (4) 3 (2) 6 (5) 0 (0)
Double positive 2 (2) 14 (14) 11 (11) 3 (3) 1 (1) 14 (13) 10 (10) 2 (2)
Double negatve 7 (0) 9 (6) 14 (6) 4 (4) 8 (1) 9 (3) 7 (6) 8 (6)
Numbers in parentheses indicate definitive osteoblast-lineage colonies retrospectively-identified by replica plating.
doi:10.1371/journal.pone.0011782.t001
Figure 2. Gene expression profling of osteoblast/adipocyte markers in single cell-derived ObL colonies and their osteo-adipogenic
potential. Numbers in each column denote relative mRNA levels of osteoblast- and adipocyte-related markers by qRT-PCR. Light blue, blue and dark
blue denote categories of expression levels, and are relatively low (1.0–1.9), intermediate (2.0–2.9) and high ($3.0), respectively. Blank space,
Undetectable. S, Stage-1, immature; 2, intermediate; 3, mature, according to expression profiling of osteoblast markers. IC, Individual colonies. Colors
in IC imply colonies derived from the same culture days (light green, day 12; green, day 15; dark green, day 17; olive, day 21). Run, Runx2; OC, OCN; Pc
and Pa, PPARc and PPARa, respectively; Adip, Adipsin. Subc, Colonies subcultured with BRL. Red, Oil red O positive; Gray, ALP positive; Yellow, Oil red
O/ALP double positive.
doi:10.1371/journal.pone.0011782.g002
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subcultures of the ALP
+ fraction revealed that the subcellular
localization of Runx2 did not differ between cells treated or not
with BRL for 12 h, whereas PPARc was primarily localized in the
nucleus in the presence but not absence of BRL (Fig. 5A).
Consistent with this, some cells within the ALP
+ fraction and
positive for nuclear Runx2 were also positive for nuclear PPARc
but not for Sox9 (Fig. 5B). In parallel cultures, BRL increased
PPARc and adipsin, but did not alter mRNA levels of other
transcription factors or OCN by 24 h post-induction (Fig. 5C-H).
These results suggest that some ObL cells express PPARc that
remains in the cytoplasm, while others can mobilize PPARc to the
nucleus; it is presumably these latter cells that convert into
adipocytes under the stimulus of PPARc-specific ligands.
Discussion
A comprehensive in vitro analysis of the effects of BRL on osteo-
adipogenic potential in the ALP
+ fraction of rat calvaria cells and
in retrospectively identified single cell-derived definitive ObL
colonies from rat calvaria cells suggests that developmentally-
regulated endogenous levels of PPARs contribute to the potential
of ObL cells to convert to adipocytes in the presence of BRL. We
also suggest that ObL cells are heterogeneous with respect to
expression of non-osteoblastic phenotypic traits, and capacity for
alternative fate choices with at least some maintaining capacity for
fate switches even at relatively late osteoblast differentiation stages.
Table 2. Expression levels of PPAR and C/EBP mRNAs in ObL
colonies correlates with their osteo-adipogenic potential
when subcultured in the presence of BRL.
Number of colonies 19 30 32
Staining pattern in
subcultures ORO ORO/ALP ALP
Relative mRNA levels PPARc 2.2261.18
a 1.8260.95
a 0.2460.58
PPARa 2.1861.22
a 1.0161.22
b, c 0.3560.53
C/EBPa 0.7160.78 1.1261.06 1.1260.84
C/EBPd 0.2160.42 0.4760.71 0.4460.98
ORO, Oil red O positive; ALP, ALP positive; ORO/ALP, Oil red O/ALP double
positive in subcultures with BRL.
ap,0.001 and
bp,0.01, compared to matched ALP.
cp,0.05, compared to matched.
doi:10.1371/journal.pone.0011782.t002
Figure 3. RS modifies the BRL effects in RC cell population cultures. Cells in osteogenic medium were chronically treated with or without BRL
in combination with or without RS or fenofibrate for 14 days. (A and B) A combination of 100 nM BRL and 1–2.5% RS elicits a reciprocal increase in
adipocytes (A) and decrease in bone nodules (B). Cells were double stained with ALP and oil red O. (C) RS does not change the total colony number in
BRL/RS-treated cultures. Cells were plated at very low density as described in Fig. 1 and maintained for 21 days with or without 100 nM BRL plus 2.5%
RS. (D) RS increases the mRNA levels of PPARa and C/EBPd but not PPARc and PPARd. Total RNA was isolated from cultures on day 14, and qRT-PCR
was performed. (E and F) Fenofibrate (Fen, 100 nM) does not substitute for RS in BRL-treated cells. Fenofibrate (100 nM) did not completely mimic
the RS effect on adipocyte colony (E) and bone nodule (F) formation. ***p,0.001, **p,0.01 and *p,0.05, compared to BRL alone.
doi:10.1371/journal.pone.0011782.g003
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and in vitro including ours [18], all support a model in which
adipocytes form at the expense of osteoblasts, which may be
processed at least in part by the PPARc-mediated downregulation
of Runx2 [16,28]. Only a few studies have addressed adipogenic
potential in the calvaria cell model. Runx2-deficient calvaria cells
show adipo-chondrogenic bipotentiality [29], and the mouse
calvaria-derived cell line MC3T3-E1 displays increased adipogen-
esis and decreased osteoblastogenesis with retroviral overexpres-
sion of PPARc [30]. However, because the cells in both these
latter models had lost the typical osteoblastic features before
analysis, it is difficult to define unambiguously which particular
ObL cells undergo transdifferentiation into adipocytes. Sorting
ObL cells based on expression of ALP, a well-established
osteoblast marker, allows enrichment for immature versus more
mature osteoblastic precursors [23]. Thus, BRL-dependent
adipogenesis in the ALP
+ fraction of ObL cells suggests that not
only immature but also maturing osteoblastic cells exhibit
adipogenic potential. A combination of limiting dilution single
colony assays and replica plating is a useful technique to trap cells
at definable developmental stages [24,25]. In spite of the possibility
of a gradient in the proliferation-differentiation sequence from the
periphery to the center of developing bone colonies [31], the
uniform ALP staining we saw in colonies selected here and the lack
of a relationship between the colony size (not shown) and their
developmental stage suggest that a development gradient, if
present under our culture conditions, was restricted to a narrow
range. Using this approach, we found a statistically significant
difference in the adipogenic potential amongst colonies defined as
being at three development stages: immature, intermediate and
mature, but adipocytes were found in all three.
Ectopic overexpression of PPARc [30] or treatment with high
doses of PPARc ligands [8,9,10,11,16] in several models elicits
reciprocal up- and downregulation of adipogenesis and osteoblas-
togenesis, respectively. On the other hand, BRL at relatively low
concentrations has no pro-adipogenic effect in MC3T3-E1 cells
[32]. Because high concentrations of PPARc and/or their ligands
may abrogate their specificity on downstream target genes [33],
we used BRL at a maximum concentration of 100 nM. Indeed, we
found that BRL (#100 nM) does not induce adipocytes in
MC3T3-E1 cells without PPARc overexpression (data not shown),
in agreement with previous data [32]. We also showed previously a
clear difference in the capacity of BRL to alter the fate choice of
precursor cells in stromal (bone marrow) versus calvaria-derived
cell populations [18], and now characterize the distinct subset of
ObL cells having adipogenic potential.
Fatty acid-rich RS increases PPARc and PPARa mRNA
expression in various osteoblastic cell lines (MB1.8, ROS17/2.8
and SaOS-2/B10) with a resultant decrease in ALP activity and
increase in adipocyte number [26]. Likewise, we found that RS in
combination with BRL mimicked the reciprocal effect of BRL on
osteogenesis versus adipogenesis in bone marrow cells. However,
Figure 4. Subcellular distribution of mesenchymal lineage determinants in RC cells. Cells were cultured without BRL as described in Fig. 1.
Proliferating cells (day3) (A), differentiating/nodule-forming cells (day 12) (B), and subcultures of differentiating/nodule-forming cells, i.e., cells from
ALP
+ fractions in developing RC cells (day 10) (C) were subjected to immunofluorescence staining for Runx2, PPARc, Sox9, and MyoD. Left-side panels
of A and B show proliferating and nodule-forming cells, respectively, by phase-contrast microscopy.
doi:10.1371/journal.pone.0011782.g004
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because the PPARa activator fenofibrate was unable to substitute
completely for RS. It is also worth noting that different PPARc
ligands have differential effects on osteo-adipogenesis in vitro and
in vivo and that the adipogenic and anti-osteogenic processes can
be regulated independently [9,34,35]. For example, additional
factors such as the basic-leucine zipper class of transcription
factors, C/EBPa, b and d, are known to participate in
adipogenesis [14]. Ectopic co-overexpression of C/EBPa and
PPARc induces adipogenesis in the G8 myoblast cell line [36] as
well as in MC3T3-E1 cells [30]. Although it was fairly widely
expressed in diverse colony types, we did not find a significant
correlation between levels of C/EBPa and adipogenic potential in
the single cell-derived colony assay. Results with viral-mediated
dual expression of C/EBPa and bone morphogenetic protein
(BMP)2 in C2C12 myoblasts suggest that C/EBPa may bias
BMP2-induced osteoblasts towards adipogenesis [37]. In contrast,
it is known that C/EBPb/d and Runx2 interact to enhance OCN
transcription [38]. Taken together, the data indicate that these
multiple transcription factors act together within carefully
regulated levels to determine osteo-adipogenic lineage progression.
PPARs and their downstream targets (e.g., adipsin, [39]) are
expressed during osteoblast development in our rat calvaria ObL
model as well as two other independent in vitro osteoblastic
models [17,26]. However, mouse calvaria cells were reported to be
more developmentally restricted than those multipotential mesen-
chymal cells expressing myoblast markers in addition to osteogenic
or adipogenic markers, and were reported not to express PPARc
during osteogenic differentiation [17]. While our data are in
general agreement, with detectable expression of several mesen-
chymal lineage determinants in rat calvaria ObL cells, we also
detected PPARc at both RNA and protein levels. However, our
data suggest that the majority of the PPARc, as well as Sox9 and
MyoD, are transcriptionally inactive and have no functional
consequences since they are abundant in the cytoplasm but not the
nucleus throughout osteoblast differentiation. It is known that the
PPARc natural ligand 15-deoxy-D12,14-prostaglandin J2 (15d-
PGJ2) induces nuclear translocation of PPARc in mouse bone
marrow stromal cells, whereas the reagent inhibits nuclear binding
of Runx2 to DNA in the MC3T3-E1 and ST2 cells, in association
with its adipogenic and anti-osteogenic activities [40]. Although
the dynamics of nucleocytoplasmic shuttling of PPARc in the
presence of BRL are poorly understood, we found that BRL
promoted the nuclear translocation of PPARc in only a discrete
subset of ObL cells and, indeed, Runx2/PPARc-double nuclear-
positive cells were occasionally observed. Likewise, Sox9, when
activated, over-rides Runx2 function in ObL cells as shown by the
phenotypes seen in transgenic mice in which Sox9 is driven by the
type Ia collagen promoter [41]. Thus, activation of PPARc
(mostly c2; see also below) may over-ride Runx2 function in
collaboration with other adipogenic transcription factors, such as
PPARa and C/EBPs under specific conditions, resulting in
conversion of particular ObL cells into adipocytes, as shown here.
PPARc has two major isoforms (c1 and c2), resulting from
different promoter usage and alternative splicing. PPARc2i s
restricted predominantly to adipose tissue where it is crucial for
adipogenesis, but the adipogenesis seen in PPARc splice variant-
null fibroblast cell lines suggests functional similarity between the
isoforms [42]. Both PPARc1 and c2 are expressed in primary
osteoblastic cells from human cancellous bone [43], while the
mouse MC3T3-E1 cell line does not express PPARc2 which led to
the suggestion that PPARc1 positively regulates osteoblastogenesis
in this model [32]. Consistent with this view, osteogenic
differentiation is correlated with upregulation of PPARc1 (and
the alternative transcripts c3 and c4) in two human osteoblast cell
lines, SV-HFO and NHOST, and human mesenchymal stem cells
[44]. Our observation that BRL enhanced nuclear translocation of
PPARc in ObL cells and increased CFU-ALP colonies begs the
question of why bone nodule formation is maintained despite
increased adipogenesis in ObL cultures treated with BRL. Our
data suggest that PPARc2 may have adipogenic and anti-
osteogenic potential, while PPARc1 may stimulate osteoblasto-
genesis, a possibility supported by results from microarray analysis
of the mouse bone marrow cell line U-33 ectopically overexpress-
ing PPARc. In this genetically-engineered line, rosiglitazone up-
and downregulates a large number of genes involved in multiple
Figure 5. BRL promotes PPARc actions in osteoblast-lineage
cells. ALP
+ fractions isolated from developing RC cells (day10) were
subcultured with or without 100 nM BRL as described in Fig. 1E-G. (A)
BRL increases relative abundance of PPARc in the nucleus versus the
cytoplasm. Cells at confluence were treated with or without 100 nM
BRL for 12 h, and subcellular fractionation was performed. The nuclear
and cytosolic fractions were subjected to Western blotting for PPARc
and Runx2. (B) Double PPARc and Runx2 nuclear positive cells are
present in cells cultured with BRL. After 2 days of plating, cells were
treated with or without 100 nM BRL for 12 h, fixed and double stained
with aRunx2 (green) and either aPPARc or aSox9 (red). (C) PPARc and
adipsin mRNA levels are selectively increased by BRL. Cells at
confluence were treated with or without 100 nM BRL for 24 h. Total
RNA was extracted, and qRT-PCR for genes tested was carried out as
shown in Fig. 3D.
doi:10.1371/journal.pone.0011782.g005
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determinants Runx2, Dlx5, Osterix [45]. Thus, PPARc may be
able to modulate osteoblast differentiation both dependently and
independently of its negative effect on ObL determinants, and at
multiple developmental stages.
In summary, we report that ObL cells co-express Runx2 and
either PPARc, Sox9, MyoD or a combination of regulatory factors
for multiple mesenchymal lineages but while Runx2 translocates to
the nucleus during osteogenic differentiation, the latter do not,
rendering them inactive under osteogenic differentiation condi-
tions. However, activation of PPARc by treatment with its
synthetic ligand, BRL, promotes nuclear translocation of PPARc
and induces an adipogenic fate switch in a discrete subset of ObL
cells characterized by relatively high levels of endogenous PPARs.
The molecular basis by which this subset of osteogenic cells
acquires high endogenous expression of adipogenic transcription
factors, whether regulated or occurring stochastically, remains to
be determined.
Materials and Methods
Ethics Statement
Animal use and procedures were approved by the Institutional
Animal Care and Use Committee at the Central Institute for
Experimental Animals and the Committee of Animal Experimen-
tation at Hiroshima University (#A09-36) and by the University of
Toronto Animal Care Committee (#20008196).
ObL cell culture
Cells were isolated from 21-day-old fetal Wistar rat calvariae by
sequential collagenase (Type I; Sigma-Aldrich) digestion as
described [46]. Cells from the last four fractions were separately
grown in aMEM supplemented with 10% fetal bovine serum
(Biological Industries) and antibiotics for 24 h. The cells were then
trypsinized, pooled and grown at 0.35610
4 cells/cm
2 in the same
medium supplemented additionally with 50 mg/ml ascorbic acid
(osteogenic medium). In particular experiments, cells were treated
with or without BRL (#100 nM) either in combination with or
without RS (#2.5%) or in combination with fenofibrate
(#100 nM), a synthetic ligand for PPARa.
CFU assay
Cells were plated at 150 cells per well in 96-well plates in
osteogenic medium with or without 1–100 nM BRL for 10 days
and double-stained with the diazo method (CFU-ALP) and oil red
O (CFU-adipocyte) (see below).
Replica plating of single cell-derived colonies
Cells were plated at limiting dilution (#15 cells/cm
2 in 100-mm
dishes) in osteogenic medium plus 10 nM dexamethosone (Dex), a
stimulator of osteoblast differentiation in this model [47]. A few
days later, polyester cloths (1 mm pore size) were placed over
developing colonies for 24 h, then transferred upside down into
new dishes with fresh osteogenic medium plus 10 nM Dex and
10 mM b-glycerophosphate (bGP) (replica dishes) [18,24,25].
Replica dishes were terminated at day 25 and subjected to ALP/
von Kossa staining (see below). On days 12, 15, 17, and 21,
colonies in master dishes were gently scraped from the dishes by
using forceps and digested with trypsin and collagenase. The
resulting cell suspension from each colony was split in half; one
half was subjected to total RNA extraction and the other half was
subcultured (,2610
4/cm
2) in osteogenic medium with 100 nM
BRL. All cultures were maintained at 37uC in a humidified
atmosphere with 5% CO2 and medium was changed every second
or third day.
Magnetic cell sorting
Differentiating cells in osteoid-like nodules (,day10 of culture)
were digested with collagenase and trypsin, and the resultant cell
suspension was incubated with biotinylated anti-ALP antibody
(40 ml/5610
6 cells; R&D systems, Minneapolis, MN) for 20 min
at 4uC. After washing, the cells were labeled with anti-biotin
magnetic microbeads (5 ml/5610
6 cells; Miltenyi Biotec) for 20
minutes at 4uC and applied onto a magnetic column (Miltenyi
Biotec). After collection of the ALP pass-through fraction (ALP
2),
the column was removed from the magnetic field and the ALP
+
fraction was flushed out according to the manufacturer’s
instructions. Control cells were prepared through the same process
but with normal mouse IgG in place of anti-ALP antibody. An
aliquot of each cell fraction (,2.5610
4 cells/cm
2) was replated
and incubated in osteogenic medium with or without 100 nM
BRL; the remainder of each fraction was used to measure ALP
activity.
ALP activity
Cells were washed with PBS and lysed by freeze-thawing (two
times) in 0.05% TritonX 100. After centrifugation, ALP activity in
cell lysates was measured with a LabAssay
TM ALP assay kit (Wako
Chemical) according to the manufacturer’s instructions.
ALP/von Kossa/oil red O staining
Cells were rinsed with PBS and fixed in 10% neutral buffered
formalin. For ALP staining, the cells were incubated with naphthol
AS MX/red violet or blue in 0.1M Tris-HCl (pH 8.3) as described
elsewhere [46]. Matrix mineralization was confirmed by further
incubation with 2.5% silver nitrate solution. For adipocytes, fixed
or ALP-stained cells were air-dried and incubated in oil red O
[48].
RT-PCR
Total RNA was isolated from cells with TRIzol reagent
(Invitrogen). Two micrograms of total RNA was reverse-
transcribed by ReverTra Ace (Toyobo) at 50uC for 40 min. The
sequence of primer sets for rat C/EBPa and d [49,50], OPN, ALP,
BSP, OCN, and ribosomal protein L32 (internal control) were
described elsewhere [47]; rat Runx2, PPARc (directed to
sequences in the 39 end of the common region of c1 and c2),
PPARc1, PPARc2, PPARa, MyoD, Sox9, lipoprotein lipase (LPL)
and adipsin were designed using Primer Picking (primer 3) (Table
S2). qRT-PCR was carried out according to the manufacturer’s
instructions (LightCycler; Roche Diagnostics) by using a SYBR
Green 1 kit.
Adaptor ligation-mediated PCR
To determine gene expression in single cell-derived colonies
with limited cell number, high-fidelity global mRNA amplification
was performed (TALPAT, T7 RNA polymerase promoter-
attached, adaptor ligation-mediated, and PCR amplification
followed by in vitro T7-transcription) [51]. Amplified cRNA was
then reverse-transcribed, and qPCR was performed as above.
Immunofluoroscence microscopy
Cells on coverslips were washed with PBS, fixed with ice-cold
acetone and air-dried. Cells were then pretreated with Dako
R
Protein Block at room temperature (RT) for 1 h, followed by
incubation with primary antibodies (Runx2, PPARc, Sox9, and
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Cy
TM3- and/or Cy
TM2-conjugated secondary antibodies (1:400;
Jackson Immunoresearch Laboratories) were used at RT for 1 h.
Each incubation step was followed by two washes with PBS (5
minutes each). As negative control, normal goat or rabbit IgG
(Vector) replaced primary antibodies.
Western blotting
Cells were lysed with 100 mM KCl, 1 mM EDTA, 0.5%
Nonidet P-40, 1 mM phenylmethylsulfonylfluoride and complete
protease inhibitor (Roche Diagnostics) in 50 mM Tris-HCl
(pH 7.5). Subcellular fractionation was carried out with a
Qproteome Cell Compartment kit (Qiagen). Aliquots of samples
were subjected to SDS-PAGE on 10–15% gels under reducing
conditions and electroblotted onto nitrocellulose membranes. The
membranes were treated with primary antibodies as above (1:500)
at 4uC overnight. The membranes were then incubated with
horseradish peroxidase-conjugated secondary antibody (1:2,000,
Santa Cruz Biotechnology), followed by chemiluminescence
detection. Anti-b-actin antibody (1:1,000, Santa Cruz Biotechnol-
ogy) was used as control.
Statistical Analysis
Unless otherwise specified, data from triplicate samples are
expressed as the mean 6 SD, and a minimum of two independent
experiments were performed. Statistical differences were evaluated
by analysis of variance (ANOVA) and post hoc Student’s t-test.
Supporting Information
Figure S1 Morphological changes in RC cell population
cultures in osteogenic medium with or without BRL. Cells were
chronically treated with or without 100 nM BRL. Phase-contrast
microscopy shows images at multiple development stages. Upper
panels, because there is no morphological difference between cells
with and without BRL until cell condensation, typical images of
cells at day 3 (d3) and d6 in the presence of BRL are shown.
Middle and bottom panels, cells at d8 and d10, respectively, in the
presence (+) and absence (2) of BRL. Bottom panels are three
times higher magnifications of the upper and middle panels.
Arrows indicate adipocytes.
Found at: doi:10.1371/journal.pone.0011782.s001 (3.32 MB TIF)
Figure S2 Expression profiling of mesenchymal lineage deter-
minants in RC cell total population cultures. Cells were cultured
under osteogenic conditions. Total RNA was isolated at the times
indicated. (A) mRNA levels of Runx2, PPARc1, PPARc2, Sox9
and MyoD. Osteoblast markers such as OPN, ALP and OCN
were also determined as an index of the stage of osteoblast
development. Data are shown as relative abundance with
ribosomal protein L32 used as internal control. (I) Western
blotting of Runx2 and PPARc. Whole cell lysates were extracted
from parallel cultures to those in (A). Aliquots of samples were
subjected to SDS-PAGE, blotted onto membranes and probed
with appropriate antibodies.
Found at: doi:10.1371/journal.pone.0011782.s002 (1.48 MB TIF)
Figure S3 Gene expression profiling of MyoD and Sox9 in
single cell-derived ObL colonies. Numbers in each column denote
relative mRNA levels of MyoD (Myo) and Sox9 by qRT-PCR.
Light blue and blue are defined as in Figure 2. Blank space,
Undetectable. S, Stages; IC, Individual colonies; see definitions in
Figure 2.
Found at: doi:10.1371/journal.pone.0011782.s003 (2.62 MB TIF)
Table S1 Osteo-adipogenic potential of indivisual colonies in the
presence of BRL. Repl, Colony types identified by replica (Repl)
plating, i.e., osteoblast (+) or non-osteoblast lineage (2). Subc,
Staining patterns/developmental outcome in colonies subcultured
(Subc) in the presence of BRL. ID, Colony ID. O, Oil red O
positive; A, ALP positive; O/A, Oil red O/ALP double positive in
subcultures with BRL.
Found at: doi:10.1371/journal.pone.0011782.s004 (0.16 MB
DOC)
Table S2 Primer sequences for qRT-PCR.
Found at: doi:10.1371/journal.pone.0011782.s005 (0.04 MB
DOC)
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